On Tuesday 06/04/2024 the closing price of the Pfizer Inc. share was $29.54 on BTT.
Compared to the opening price on Tuesday 06/04/2024 on BTT of $29.34, this is a gain of 0.68%.
Pfizer Inc.'s market capitalization is $162.11 B by 5.67 B shares outstanding.
Is Pfizer stock a Buy, Sell or Hold?
Pfizer stock has received a consensus rating of hold. The average rating score is A2 and is based on 28 buy ratings, 38 hold ratings, and 0 sell ratings.What was the 52-week low for Pfizer stock?
The low in the last 52 weeks of Pfizer stock was 25.21. According to the current price, Pfizer is 117.18% away from the 52-week low.What was the 52-week high for Pfizer stock?
The high in the last 52 weeks of Pfizer stock was 40.36. According to the current price, Pfizer is 73.19% away from the 52-week high.What are analysts forecasts for Pfizer stock?
The 66 analysts offering price forecasts for Pfizer have a median target of 48.00, with a high estimate of 75.00 and a low estimate of 27.00. The median estimate represents a 61.54 difference from the last price of 29.54.Pfizer Stock Snapshot
29.50
Bid
4,233.00
Bid Size
29.51
Ask
589.00
Ask Size
6/4/2024
Date
6:17 PM
Time
1.70 M
Volume
29.50
Prev. Close
29.34
Open
162.11 B
Market Cap
5.67 B
Number of Shares
29.17
Day Low
29.73
Day High
29.54
25.21
52 Week Low
40.36
52 Week High
29.54
6.02
Dividend Yield
15.65
P/E Ratio
99.96
Free Float in %
2.35
EPS 2024
15.34
Book Value per Share
2.61
Cash Flow per Share
Pfizer News More News
Historical Prices for Pfizer
Date | Open | Close | Daily High | Daily Low |
---|
Price change over selected period:
0%
0
Pfizer Analyst Data
Total Analysts: 66
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 27.00
Median: 48.00
Highest: 75.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Pfizer Analyst Opinions
- All
- Buy
- Hold
- Sell
Date | Analyst | Rating | Price | |||
---|---|---|---|---|---|---|
05/02/24 | Morgan Stanley | Maintained Hold | $29 | |||
05/02/24 | BMO Capital Markets | Maintained Buy | $36 | |||
04/18/24 | Cantor Fitzgerald | Maintained Buy | $45 | |||
04/15/24 | Cantor Fitzgerald | Maintained Buy | $45 | |||
04/05/24 | Cantor Fitzgerald | Maintained Buy | $45 | |||
04/01/24 | Cantor Fitzgerald | Maintained Buy | $45 | |||
03/22/24 | Argus Research Company | Downgraded to Hold | ||||
03/04/24 | Cantor Fitzgerald | Maintained Buy | $45 | |||
03/01/24 | Cantor Fitzgerald | Maintained Buy | $45 | |||
02/23/24 | Guggenheim | Maintained Buy | $36 | |||
01/31/24 | Cantor Fitzgerald | Maintained Buy | $45 | |||
01/09/24 | Cantor Fitzgerald | Maintained Buy | $45 | |||
12/14/23 | UBS | Maintained Hold | $27 | |||
12/14/23 | Barclays Capital | Maintained Hold | $28 | |||
11/20/23 | Cantor Fitzgerald | Maintained Buy | $75 | |||
11/01/23 | Barclays Capital | Maintained Hold | $34 | |||
11/01/23 | Morgan Stanley | Maintained Hold | $37 | |||
10/20/23 | UBS | Maintained Hold | $34 | |||
10/17/23 | Morgan Stanley | Maintained Hold | $39 | |||
10/16/23 | BMO Capital Markets | Maintained Buy | $33 | |||
10/16/23 | Citigroup Corp. | Maintained Hold | $35 | |||
10/16/23 | J.P. Morgan | Maintained Hold | $34 | |||
10/16/23 | Wells Fargo & Co | Maintained Hold | $35 | |||
10/06/23 | J.P. Morgan | Maintained Hold | $36 | |||
10/02/23 | Cantor Fitzgerald | Maintained Buy | $75 | |||
09/18/23 | Cantor Fitzgerald | Maintained Buy | $75 | |||
09/05/23 | Cantor Fitzgerald | Maintained Buy | $75 | |||
08/30/23 | Cantor Fitzgerald | Maintained Buy | $75 | |||
08/22/23 | Cantor Fitzgerald | Maintained Buy | $75 | |||
08/02/23 | Morgan Stanley | Maintained Hold | $40 | |||
08/02/23 | BMO Capital Markets | Maintained Buy | $44 | |||
07/21/23 | Morgan Stanley | Maintained Hold | $42 | |||
07/11/23 | Morgan Stanley | Maintained Hold | $43 | |||
07/11/23 | Barclays Capital | Maintained Hold | $38 | |||
06/29/23 | Credit Suisse | Downgraded to Hold | $40 | |||
06/22/23 | Cantor Fitzgerald | Maintained Buy | $75 | |||
05/17/23 | Cantor Fitzgerald | Maintained Buy | $75 | |||
05/11/23 | Daiwa Securities | Downgraded to Hold | $38 | |||
05/03/23 | Credit Suisse | Maintained Buy | $47 | |||
05/03/23 | Barclays Capital | Maintained Hold | $40 | |||
04/21/23 | Bank of America Merrill Lynch | Maintained Hold | $45 | |||
04/12/23 | Barclays Capital | Maintained Hold | $43 | |||
04/10/23 | Morgan Stanley | Maintained Hold | $44 | |||
03/17/23 | Wells Fargo & Co | Maintained Hold | $44 | |||
02/07/23 | Daiwa Securities | Upgraded to Buy | $51 | |||
02/01/23 | Morgan Stanley | Maintained Hold | $45 | |||
02/01/23 | Cantor Fitzgerald | Maintained Buy | $75 | |||
02/01/23 | Credit Suisse | Maintained Buy | $50 | |||
02/01/23 | BMO Capital Markets | Maintained Buy | $53 | |||
02/01/23 | Barclays Capital | Maintained Hold | $44 |
Pfizer Estimates* in USD
2024 | 2025 | 2026 | 2027 | 2028 | |
---|---|---|---|---|---|
Revenue | 60,520 | 62,686 | 63,053 | 64,321 | - |
Dividend | - | - | - | - | 1.76 |
Dividend Yield (in %) | 6.02 % | 6.15 % | 6.19 % | 6.26 % | 6.00 % |
EPS | 2.35 | 2.73 | 2.87 | 3.03 | 2.90 |
P/E Ratio | 12.49 | 10.76 | 10.21 | 9.69 | 10.13 |
EBIT | 17,287 | 19,329 | 20,275 | 21,102 | 19,880 |
EBITDA | 21,031 | 23,329 | 24,248 | 24,674 | - |
Net Profit | 13,430 | - | - | 17,491 | 16,794 |
Net Profit Adjusted | 13,430 | 15,609 | 16,469 | 17,491 | 16,794 |
Pre-Tax Profit | 15,893 | - | 19,630 | 20,885 | 19,851 |
Net Profit (Adjusted) | 13,394 | 15,761 | 16,015 | 12,580 | 11,780 |
EPS (Non-GAAP) ex. SOE | 2.35 | 2.73 | 2.87 | 3.03 | 2.90 |
EPS (GAAP) | 1.59 | 2.17 | 2.40 | 2.58 | 2.30 |
Gross Income | 43,379 | 45,585 | 46,773 | 48,500 | - |
Cash Flow from Investing | -1,564 | -3,499 | -3,467 | -3,941 | -4,384 |
Cash Flow from Operations | 16,561 | 16,928 | 18,376 | 19,872 | 20,797 |
Cash Flow from Financing | -12,882 | -12,173 | -12,849 | -11,311 | -11,901 |
Cash Flow per Share | 2.61 | 2.92 | 2.91 | 2.68 | - |
Free Cash Flow | 11,027 | 12,327 | 13,729 | 12,915 | - |
Free Cash Flow per Share | 2.15 | 2.33 | 2.58 | - | - |
Book Value per Share | 15.34 | 15.48 | 15.75 | 15.11 | 16.31 |
Net Debt | 59,600 | 55,251 | 50,180 | 56,196 | - |
Research & Development Exp. | 11,608 | 11,767 | 11,863 | 11,987 | - |
Capital Expenditure | 2,976 | 3,007 | 3,001 | 3,187 | 3,991 |
Selling, General & Admin. Exp. | 14,594 | 14,801 | 14,479 | 14,907 | - |
Shareholder’s Equity | 90,296 | 90,790 | 92,313 | 100,777 | 112,628 |
Total Assets | 218,260 | 216,464 | 214,849 | 219,000 | 232,904 |
Previous Quarter ending 03/31/24 |
Current Quarter ending 06/30/24 |
Next Quarter ending 09/30/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
---|---|---|---|---|---|
Earnings Estimates | |||||
No. of Analysts | 15 | 17 | 17 | 21 | 21 |
Average Estimate | 0.516 USD | 0.453 USD | 0.538 USD | 2.348 USD | 2.727 USD |
Year Ago | 1.230 USD | 0.670 USD | -0.170 USD | 1.840 USD | 2.348 USD |
Publish Date | 5/1/2024 | 7/30/2024 | 10/29/2024 | - | - |
Revenue Estimates | |||||
No. of Analysts | 15 | 15 | 15 | 20 | 20 |
Average Estimate | 13,874 USD | 13,034 USD | 14,784 USD | 60,520 USD | 62,686 USD |
Year Ago | 18,282 USD | 12,734 USD | 13,232 USD | 58,496 USD | 60,520 USD |
Publish Date | 5/1/2024 | 7/30/2024 | 10/29/2024 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements
2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|
Sales | 52,546 | 53,647 | 51,750 | 41,908 | 81,288 | 100,330 | 58,496 |
Change of sales in % | -0.53 | 2.10 | -3.54 | -19.02 | 93.97 | 23.43 | -41.70 |
Gross profit on sales | 36,757 | 37,639 | 37,011 | 29,843 | 46,875 | 62,090 | 29,283 |
Gross profit on sales change in % | -0.31 | 2.40 | -1.67 | -19.37 | 57.07 | 32.46 | -52.84 |
Operating income | 14,425 | 15,289 | 14,117 | 9,018 | 20,793 | 37,549 | 4,235 |
Operating income change in % | 1.06 | 5.99 | -7.67 | -36.12 | 130.57 | 80.58 | -88.72 |
Income before tax | 12,305 | 11,885 | 17,682 | 7,497 | 24,311 | 34,729 | 1,058 |
Income before tax change in % | 47.35 | -3.41 | 48.78 | -57.60 | 224.28 | 42.85 | -96.95 |
Income after tax | 21,305 | 11,153 | 16,273 | 9,616 | 22,147 | 31,365 | 2,133 |
Income after tax change in % | 195.29 | -47.65 | 45.91 | -40.91 | 130.31 | 41.62 | -93.20 |
Balance Sheet
2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|
Total liabilities | 100,141 | 95,664 | 104,044 | 90,756 | 104,013 | 101,288 | 137,213 |
Total liabilities change in % | 11.66 | 11.16 | 12.06 | 11.65 | 10.91 | 10.53 | 15.84 |
Equity | 71,656 | 63,758 | 63,445 | 63,473 | 77,463 | 95,917 | 89,288 |
Equity change in % | 19.77 | -11.08 | -0.41 | 0.18 | 22.08 | 23.91 | -6.95 |
Balance sheet total | 171,797 | 159,422 | 167,489 | 154,229 | 181,476 | 197,205 | 226,501 |
Balance sheet total change in % | 0.11 | -7.20 | 5.06 | -7.92 | 17.67 | 8.67 | 14.86 |
Key Data
2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|
Sales per share | 8.67 | 8.98 | 9.12 | 7.44 | 14.24 | 17.50 | 10.25 |
P/E ratio (year end quote, basic EPS) | 10.30 | 23.39 | 13.66 | 21.56 | 15.22 | 9.37 | 76.67 |
P/E ratio (ear end quote, diluted EPS) | 10.30 | 23.39 | 13.66 | 21.56 | 15.22 | 9.37 | 76.67 |
P/E ratio (year end quote) | 10.30 | 23.39 | 13.66 | 21.56 | 15.22 | 9.37 | 76.67 |
Dividend yield in % | 3.59 | 3.16 | 3.73 | 4.16 | 2.66 | 3.14 | 5.73 |
Equity ratio in % | 41.49 | 39.76 | 37.69 | 41.00 | 42.54 | 48.51 | 39.30 |
Debt ratio in % | 58.29 | 60.01 | 62.12 | 58.84 | 57.32 | 51.36 | 60.58 |
Pfizer Insider Activity
Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
---|---|---|---|---|---|---|
BOSHOFF CHRISTOFFEL | 02/27/2024 | 4,150.00 | 156,007.00 | 27.04 | Sell | No |
BOSHOFF CHRISTOFFEL | 02/27/2024 | 11,510.00 | 160,157.00 | n/a | Buy | No |
DAMICO JENNIFER B. | 02/26/2024 | 5,113.00 | 13,495.00 | n/a | Buy | No |
de Germay Alexandre | 02/26/2024 | 74,377.00 | 74,377.00 | n/a | Buy | No |
McDermott Michael | 02/25/2024 | 6,063.00 | 75,463.00 | 27.18 | Sell | No |
DAMICO JENNIFER B. | 02/24/2024 | 1,386.00 | 8,382.00 | 27.76 | Sell | No |
McDermott Michael | 02/24/2024 | 2,992.00 | 81,526.00 | 27.76 | Sell | No |
DAMICO JENNIFER B. | 02/23/2024 | 354.00 | 9,768.00 | 27.76 | Sell | No |
DAMICO JENNIFER B. | 02/22/2024 | 7,881.00 | 10,122.00 | 27.37 | Sell | No |
DAMICO JENNIFER B. | 02/22/2024 | 774.00 | 18,003.00 | 27.76 | Sell | No |
DAMICO JENNIFER B. | 02/22/2024 | 451.00 | 18,777.00 | 27.76 | Sell | No |
JOHNSON RADY A | 02/22/2024 | 23,788.00 | 97,153.00 | 27.37 | Sell | No |
JOHNSON RADY A | 02/22/2024 | 2,132.00 | 120,941.00 | 27.76 | Sell | No |
McDermott Michael | 02/22/2024 | 10,031.00 | 84,518.00 | 27.37 | Sell | No |
McDermott Michael | 02/22/2024 | 859.00 | 94,549.00 | 27.76 | Sell | No |
SUSMAN SALLY | 02/22/2024 | 51,589.00 | 161,611.00 | 27.37 | Sell | No |
SUSMAN SALLY | 02/22/2024 | 4,948.00 | 213,200.00 | 27.76 | Sell | No |
BOURLA ALBERT | 02/22/2024 | 103,178.00 | 327,739.00 | 27.37 | Sell | No |
BOURLA ALBERT | 02/22/2024 | 8,831.00 | 430,917.00 | 27.76 | Sell | No |
Dolsten Mikael | 02/22/2024 | 24,822.00 | 343,166.00 | 27.76 | Sell | No |
DAMICO JENNIFER B. | 02/22/2024 | 9,752.00 | 19,228.00 | 27.34 | Buy | No |
JOHNSON RADY A | 02/22/2024 | 29,436.00 | 123,073.00 | 27.34 | Buy | No |
McDermott Michael | 02/22/2024 | 12,412.00 | 95,408.00 | 27.34 | Buy | No |
SUSMAN SALLY | 02/22/2024 | 63,837.00 | 218,148.00 | 27.34 | Buy | No |
BOURLA ALBERT | 02/22/2024 | 127,674.00 | 439,748.00 | 27.34 | Buy | No |
Pfizer Dividend Calendar
Date | Name | Dividend | *yield | Currency |
---|---|---|---|---|
2023 | Pfizer Inc. | 1.65 | 5.73 | USD |
2022 | Pfizer Inc. | 1.61 | 3.14 | USD |
2021 | Pfizer Inc. | 1.57 | 2.66 | USD |
2020 | Pfizer Inc. | 1.53 | 4.16 | USD |
2019 | Pfizer Inc. | 1.46 | 3.73 | USD |
2018 | Pfizer Inc. | 1.38 | 3.16 | USD |
2017 | Pfizer Inc. | 1.30 | 3.59 | USD |
2016 | Pfizer Inc. | 1.22 | 3.76 | USD |
2015 | Pfizer Inc. | 1.14 | 3.53 | USD |
2014 | Pfizer Inc. | 1.06 | 3.40 | USD |
2013 | Pfizer Inc. | 0.98 | 3.20 | USD |
2012 | Pfizer Inc. | 0.90 | 3.59 | USD |
2011 | Pfizer Inc. | 0.82 | 3.79 | USD |
2010 | Pfizer Inc. | 0.74 | 4.23 | USD |
2009 | Pfizer Inc. | 0.66 | 3.63 | USD |
2008 | Pfizer Inc. | 1.28 | 7.23 | USD |
2007 | Pfizer Inc. | 1.16 | 5.10 | USD |
2006 | Pfizer Inc. | 0.96 | 3.71 | USD |
2005 | Pfizer Inc. | 0.76 | 3.26 | USD |
2004 | Pfizer Inc. | 0.68 | 2.53 | USD |
2003 | Pfizer Inc. | 0.60 | 1.70 | USD |
2002 | Pfizer Inc. | 0.52 | 1.70 | USD |
2001 | Pfizer Inc. | 0.44 | 1.10 | USD |
2000 | Pfizer Inc. | 0.36 | 0.78 | USD |
1999 | Pfizer Inc. | 0.31 | USD |
*Yield of the Respective Date
Pfizer Inc. Calendar
Event | Estimate | Info | Date |
---|---|---|---|
Earnings Report | 0.453 USD | Q2 2024 Earnings Release | 07/30/2024 |
Earnings Report | 0.538 USD | Q3 2024 Earnings Release | 10/29/2024 |
Earnings Report | - | Q4 2024 Earnings Release | 02/04/2025 |
Earnings Report | - | Q1 2025 Earnings Release | 05/06/2025 |
Pfizer Inc. Past Events
Event | Actual EPS | Info | Date |
---|---|---|---|
Earnings Report | 0.820 USD | Q1 2024 Earnings Release | 05/01/2024 |
Annual General Meeting | - | Annual General Meeting | 04/25/2024 |
Press Conference | - | - | 01/30/2024 |
Press Conference | - | - | 10/31/2023 |
Press Conference | - | - | 08/01/2023 |
Pfizer Profile
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Moody’s Daily Credit Risk Score
Pfizer Shareholder
Owner | in % |
---|---|
Freefloat | 99.96 |
The Vanguard Group, Inc. | 8.97 |
Vanguard Group, Inc. (Subfiler) | 8.54 |
State Street Corp. | 5.15 |
SSgA Funds Management, Inc. | 5.10 |
Wellington Management Co. LLP | 3.15 |
Vanguard Total Stock Market ETF | 3.14 |
BlackRock Fund Advisors | 2.78 |
Vanguard 500 Index Fund | 2.54 |
BlackRock Institutional Trust Co. NA | 2.20 |
Charles Schwab Investment Management, Inc. | 2.16 |
Geode Capital Management LLC | 2.01 |
Capital Research & Management Co. (World Investors) | 2.00 |
Norges Bank (13F) | 1.31 |
Government Pension Fund - Global (The) | 1.29 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Pfizer Management
Name | Job |
---|---|
Albert Bourla | Chairman & Chief Executive Officer |
Aamir Malik | Chief Commercial Officer-US & Executive VP |
Sally Susman | Chief Corporate Affairs Officer & Executive VP |
Roger D. Dansey | Chief Development Officer-Oncology |
David M. Denton | Chief Financial Officer & Executive Vice President |
Michael McDermott | Chief Global Supply Officer & Executive VP |
Alexandre de Germay | Chief International Commercial Officer & EVP |
Christopher J. Stevo | Chief Investor Relations Officer & Senior VP |
Maria Rivas | Chief Medical Affairs Officer |
Aida Habtezion | Chief Medical Officer & Head-Worldwide Medical |
Luis Jodar | Chief Medical Officer-Vaccines & Senior VP |
Chris Boshoff | Chief Oncology Officer & Executive Vice President |
Payal Sahni Becher | Chief People Experience Officer & Executive VP |
Patrice Ettinger | Chief Privacy Offucer |
Jeff Settleman | Co-Chief Scientific Officer |
Mikael Dolsten | Co-Chief Scientific Officer & President-Research |
Rady A. Johnson | EVP, Chief Compliance, Quality & Risk Officer |
Denis Patrick | Executive Director & Vice President-WRDM |
Lidia L. Fonseca | Executive VP, Chief Technology & Digital Officer |
Douglas M. Lankler | Executive Vice President & General Counsel |
Dan R. Littman | Independent Director |
Helen H. Hobbs | Independent Director |
James C. Smith | Independent Director |
James Quincey | Independent Director |
Joseph J. Echevarria | Independent Director |
Ronald Edward Blaylock | Independent Director |
Scott Gottlieb | Independent Director |
Susan D. Desmond-Hellmann | Independent Director |
Susan J. Hockfield | Independent Director |
Suzanne Nora Johnson | Independent Director |
Shantanu Narayen | Lead Independent Director |
Suneet Varma | President-US Oncology Business Unit |
William C. Sessa | SVP &Chief Scientific Officer-Internal Medicine |
Annaliesa Anderson | SVP, Head-Vaccine Research & Development |
Margaret M. Madden | Secretary, Chief Governance Counsel & Senior VP |
Jennifer B. Damico | Senior Vice President & Controller |
Bryan Supran | Senior Vice President & Deputy General Counsel |
Gordon Loh | Senior Vice President-Corporate Audit |
Markus Green | Vice President & Assistant General Counsel |
Barbara J. Dalton | Vice President-Worldwide Business Development |
John DeYoung | Vice President-Worldwide Business Development |